Navigation Links
Aires Pharmaceuticals Appoints Edwin L. Parsley as Chief Medical Officer
Date:5/4/2011

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Aires Pharmaceuticals, Inc. today announced the hiring of Ed Parsley, D.O. as Chief Medical Officer.  Dr. Parsley will fill a key role on Aires' leadership team and will be responsible for all clinical development activities for Aironite™, the company's lead product for treatment of pulmonary arterial hypertension (PAH).

Dr. Parsley joins Aires from Pfizer where he was the Clinical Lead for ongoing clinical trials for Revatio (Sildenafil), Pfizer's approved drug to treat PAH, as well as the additional compounds in Pfizer's pulmonary vascular disease portfolio.  Dr. Parsley previously worked at CSL Biotherapies and Encysive Pharmaceuticals, Inc. where he was the Executive Director for Global Medical Affairs and Drug Safety developing an endothelin antagonist for pulmonary hypertension, heart failure and resistant hypertension.

Dr. Parsley is a practicing physician and Board certified in Pulmonary, Internal Medicine, Critical Care and Sleep Medicine.  Prior to joining industry, he was an assistant professor and medical director at the University of Texas Medical School at Houston.

"We are excited to welcome Ed to our team," stated Wendy Johnson, President & CEO of Aires.  "Ed brings a wealth of experience developing drugs for treatment of PAH and other pulmonary vascular diseases.  He is well-known in the PAH community and will make immediate contributions to shaping and executing our clinical development program."

About Aires

Aires Pharmaceuticals, Inc. is a privately held drug development company located in San Diego developing Aironite™ for cardiopulmonary indications such as pulmonary arterial hypertension.  In November 2010, Aires announced a $20M equity financing funded by ProQuest Investments and MPM Capital.


'/>"/>
SOURCE Aires Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. T-System Provides Free Medical Documentation Templates and Bi-Lingual Triage Questionnaires for Haiti Relief Medical Personnel
2. Buenos Aires Welcomes CPhI South America 2010
3. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
4. CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):